| Literature DB >> 29311124 |
Dejan Jakimovski1, Channa Kolb2, Murali Ramanathan2,3, Robert Zivadinov1,4, Bianca Weinstock-Guttman2.
Abstract
Despite that the availability of new therapeutic options has expanded the multiple sclerosis (MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy option in the current decision-making process. This review will summarize the present knowledge of IFN-β mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting MS and clinically isolated syndromes. Data on secondary progressive MS is also provided, although no clear benefit was identified.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29311124 DOI: 10.1101/cshperspect.a032003
Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN: 2157-1422 Impact factor: 6.915